SCHEMBL5072055

SCHEMBL5072055

Cn1cc(-c2cc3cccnc3[nH]2)c2cc(OCCC(=O)O)ccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.59
IGF1R P08069 3/20 0.57
LCK P06239 2/20 0.51
GSK3A P49840 2/20 0.51
GSK3B P49841 2/20 0.51
CDK7 P50613 2/20 0.51
LRRK2 Q5S007 2/20 0.51
AURKB Q96GD4 2/20 0.51
JAK2 O60674 1/20 0.51
BTK Q06187 1/20 0.51
AURKA O14965 1/20 0.45
PAK4 O96013 1/20 0.45
ABL1 P00519 1/20 0.45
NTRK1 P04629 1/20 0.45
FYN P06241 1/20 0.45
CSF1R P07333 1/20 0.45
RET P07949 1/20 0.45
MET P08581 1/20 0.45
PDGFRB P09619 1/20 0.45
PIM1 P11309 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1779688 0.90 SYK (0.61) SYKIGF1RLCKGSK3AGSK3B
SCHEMBL1777065 0.88 IGF1R (0.61) SYKIGF1RLCKGSK3AGSK3B
SCHEMBL1778867 0.87 IGF1R (0.60) SYKIGF1RLCKGSK3AGSK3B
SCHEMBL12606260 0.87 SYK (0.57) SYKIGF1RLCKGSK3AGSK3B
SCHEMBL12606325 0.86 IGF1R (0.61) SYKIGF1RLCKGSK3AGSK3B
SCHEMBL1778605 0.85 SYK (0.61) SYKIGF1RLCKGSK3AGSK3B
SCHEMBL12605859 0.84 IGF1R (0.58) SYKIGF1RLCKGSK3AGSK3B
SCHEMBL1779221 0.84 IGF1R (0.58) SYKIGF1RLCKGSK3AGSK3B
SCHEMBL12606261 0.83 SYK (0.61) SYKIGF1RLCKGSK3AGSK3B
SCHEMBL1777168 0.83 IGF1R (0.74) SYKIGF1RLCKGSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1990343-B1 Azaindoles AVENTIS PHARMA LTD (GB) 2012-04-04 EP disclosed
EP-1990343-A2 Azaindoles Aventis Pharma Limited (GB) 2008-11-12 EP disclosed
US-7227020-B2 Azaindoles AVENTIS PHARMA LIMITED (GB) 2007-06-05 US disclosed
US-20040198737-A1 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-10-07 US disclosed
US-6770643-B2 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-08-03 US disclosed
US-20040009983-A1 Azaindoles AVENTIS PHARMA LIMITED (GB) 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198737-A1 Azaindoles CCNY, CCNO, CNKSR1 SYK 1822/4885IGF1R 2352/4885LCK 480/4885
US-20040009983-A1 Azaindoles CCNY, CCNO, CKS2 SYK 1896/4885IGF1R 2074/4885LCK 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.